KLK3 and prostate carcinoma: Plasmatic EVs expressing both CD81 and PSA were significantly higher in prostate cancer patients compared to either healthy controls or patients with BPH, reaching 100% specificity and sensitivity in distinguishing prostate cancer patients from healthy individuals [172].